20231210-德邦证券-医药行业周报_关注IVD集采_重视中风大品种__14页_2mb

Pharmaceutical and Biotechnology Industry Weekly Analysis

Market Performance
This week, the Shenhua Pharmaceuticals and Biotech index dropped 26%, outperforming the SSE CSI 300 Index under by 0.2%. Year-to-date, the index is down 50%, but still beat the SSE CSI 300 by 7.2%. Key performers this week include Tonghua Jinma with a 3,559% increase and other high-growth stocks.

Neuroprotective Agents for Stroke
Stroke is a deadly disease with high global incidence and mortality rates. Neuroprotective drugs show strong market potential: Enbipu, a leading drug in stroke treatment, sold over $60 million in 2022; Xianbixin, a new compound, achieved $150 million in 2021 with upcoming tablet forms; and Hydroxycrocanonolide A, under development, could be another big player, pending clinical approval.

Investment Strategy
Focus on innovation, Phama companies, and emerging sectors like IVDs. Short-term outlook highlights cyclicality in fields such as IVD due to favorable procurement results, with companies like AnTu Biosciences recommended. Long-term emphasis on areas like acute care drugs, gene therapies, and globalized healthcare solutions. Specific stock recommendations include Biogen, Tianqiao Biotherapeutics, and firms like Brightspeed Pharmaceuticals.

Risks
Industry exposure to demand shortfalls, company-specific outcomes, or increased competition. Cautious investment advised due to market volatility and policy changes.